SLC5A2 and diabetes mellitus: Clinical evidence has recognized that SGLT2 inhibitors, such as dapagliflozin and empagliflozin, substantially improve the prognosis of patients with HFrEF due to their high effectiveness on CV and renal outcomes independent of diabetes status and with mechanisms other than glucose lowering.